Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression
Debarpan Guhathakurta, Aneta Petrušková, Enes Yağız Akdaş, Bartomeu Perelló-Amorós, Renato Frischknecht, Daniela Anni, Eva-Maria Weiss, Martin Walter, Anna Fejtová · FENS Forum 2024
Major depressive disorder (MDD) is a disabling psychiatric disorder and a major cause of global health burden, affecting approximately 280 million people. Traditional antidepressants primarily target the monoaminergic system, have significant side effects and leave approximately 40% of patients unresponsive to treatment. Ketamine (KET) is a fast-acting antidepressant that transiently inhibits N-methyl-d-aspartate receptors (NMDARs) to produce its antidepressant effects. KET is rapidly metabolised to hydroxynorketamine (HNK), which reduces depressive behaviour in rodents. HNK has been shown to
ePoster · Neuroscience